Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

120.88
-0.3600-0.30%
Post-market: 120.880.00000.00%19:30 EDT
Volume:21.60K
Turnover:2.61M
Market Cap:545.17M
PE:6.27
High:121.66
Open:121.66
Low:120.55
Close:121.24
52wk High:131.68
52wk Low:92.10
Shares:4.51M
Float Shares:4.51M
Volume Ratio:0.46
T/O Rate:0.48%
Dividend:1.11
Dividend Rate:0.92%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.64
PE(LYR):5.56

Loading ...

Alert on EOG CFO Appointment Incorrectly Tagged to J&J Withdrawn

Reuters
·
Sep 24

EOG Resources Announces Ann Janssen's Retirement and Jeff Hibbard as Next CFO

THOMSON REUTERS
·
Sep 24

Health Canada Approves AbbVie’s Epkinly Combo for Relapsed or Refractory Follicular Lymphoma in Adults

Reuters
·
Sep 24

Epkinly® Receives Health Canada Approval for Adults with Follicular Lymphoma

THOMSON REUTERS
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Sino Biopharmaceutical Stock Slips 1.8% in Hong Kong

Dow Jones
·
Sep 24

Leerink Partners Remains a Hold on Amgen (AMGN)

TIPRANKS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23

Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build

TradingKey
·
Sep 23

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Reuters
·
Sep 23

US Companies Face Rise in Cyber Attacks

Reuters
·
Sep 23

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

TIPRANKS
·
Sep 23

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

Reuters
·
Sep 23

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS
·
Sep 23